Cholesta-5,7,9(11)-trien-3 beta-ol found in plasma of patients with Smith-Lemli-Opitz syndrome indicates formation of sterol hydroperoxide.

The Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive disorder characterized by accumulation of cholesta-5,7-dien-3 beta-0l caused by a deficiency of the enzyme desaturating this sterol to cholesterol. In addition to other unusual sterols recently found in plasma of patients with SLOS, namely cholesta-5,8-dien-3 beta-ol and 19-nor-cholesta-5,7,9 (10)-trien-3 beta-ol we have detected a trienol and we describe here its identification as cholesta-5,7,9 (11)-trien-3 beta-ol by GC-MS and by comparison with a synthetic standard. We tested the possibility that the trienol may be formed by radical oxidation of cholesta-5,7-dien-3 beta-ol accumulated in plasma of patients with SLOS because it is known to be formed by decomposition of 7-hydroperoxy-cholesta-5,8-dien-3 beta-ol, which is a product of cholesta-5,7-dien-3 beta-ol photooxidation. Incubation of cholesta-5,7-dien-3 beta-ol with rat liver microsomes in the presence of ADP/Fe2+ and NADPH gave rise to a number of oxygenated sterols. Among these, analysis by particle-beam LC-MS under CI conditions indicated the presence of 7-hydroperoxy-cholesta-5,8-dien-3 beta-ol and of cholesta-5,7,9(11)-trien-3 beta-ol which is known to derive from the oxidation of the 7-hydroperoxide. From these results we conclude that cholesta-5,7-dien-3 beta-ol accumulated in tissues of patients with SLOS may be oxidized by oxygen radicals giving rise to oxygenated sterols. Some of these compounds may be toxic and may contribute to worsen the pathological picture in patients with SLOS.

[1]  G. Corso,et al.  Clinical and biochemical screening for Smith–Lemli–Opitz syndrome , 1996 .

[2]  G. Tint,et al.  Identification of 19-nor-5,7,9(10)-cholestatrien-3 beta-ol in patients with Smith-Lemli-Opitz syndrome. , 1995, Journal of lipid research.

[3]  A. Honda,et al.  Markedly inhibited 7-dehydrocholesterol-delta 7-reductase activity in liver microsomes from Smith-Lemli-Opitz homozygotes. , 1995, The Journal of clinical investigation.

[4]  A. Honda,et al.  Defective conversion of 7-dehydrocholesterol to cholesterol in cultured skin fibroblasts from Smith-Lemli-Opitz syndrome homozygotes. , 1995, Journal of lipid research.

[5]  G. Tint,et al.  Identification of 8-dehydrocholesterol (cholesta-5,8-dien-3 beta-ol) in patients with Smith-Lemli-Opitz syndrome. , 1995, Journal of lipid research.

[6]  A. Catapano,et al.  Evidence for the presence of 7-hydroperoxycholest-5-en-3 beta-ol in oxidized human LDL. , 1992, Chemistry and physics of lipids.

[7]  T. Miettinen,et al.  Serum and hepatic cholestanol, squalene and noncholesterol sterols in man: A study on liver transplantation , 1992, Hepatology.

[8]  J. Opitz,et al.  Smith-Lemli-Opitz syndrome-type II: multiple congenital anomalies with male pseudohermaphroditism and frequent early lethality. , 1987, American journal of medical genetics.

[9]  K. Taysi,et al.  Possible abnormalities of steroid secretion in children with Smith-Lemli-Opitz syndrome and their parents , 1985, Steroids.

[10]  E. Bosisio,et al.  Influence of species and sex on cholesterol 7α-hydroxylase activity in experimental animals , 1983 .

[11]  R. Lester,et al.  Measurement of cholesterol 7 alpha-hydroxylase activity with selected ion monitoring. , 1981, Journal of lipid research.

[12]  T. Slater,et al.  The stimulatory effects of carbon tetrachloride and other halogenoalkanes on peroxidative reactions in rat liver fractions in vitro. General features of the systems used. , 1971, The Biochemical journal.

[13]  J. Opitz,et al.  A newly recognized syndromeof multiple congenital anomalies , 1964 .

[14]  E. Mosettig,et al.  STEROIDS WITH AN AROMATIC B-RING1 , 1952 .

[15]  A. Windaus,et al.  Über die Ultraviolett-Bestrahlung des Dehydro-ergosterins , 1928 .